Methylene blue treatment delays progression of perfusion-diffusion mismatch to infarct in permanent ischemic stroke

Brain Research

Volumn 1588, Issue , 2014, Pages 144-149

  Rodriguez, Pavel ^a   Jiang, Zhao ^a,b   Huang, Shiliang ^a   Shen, Qiang ^a   Duong, Timothy Q ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Infarct volume; Ischemic penumbra Neuroprotection; Middle cerebral artery occlusion; MRI; Oxidative stress

Indexed keywords

ADENOSINE TRIPHOSPHATE; METHYLENE BLUE; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APPARENT DIFFUSION COEFFICIENT; ARTICLE; BRAIN BLOOD FLOW; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN PERFUSION; CONTROLLED STUDY; DIFFUSION; DIFFUSION COEFFICIENT; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; LOW DRUG DOSE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PERFUSION DIFFUSION MISMATCH; PHYSICAL PHENOMENA; RAT; ANIMAL; BRAIN; BRAIN CIRCULATION; CEREBRAL ARTERY DISEASE; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; INFARCTION, MIDDLE CEREBRAL ARTERY; MAGNETIC RESONANCE IMAGING; MALE; METHYLENE BLUE; NEUROPROTECTIVE AGENTS; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 84909987563     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2014.09.007     Document Type: Article

References (25)

1. J. Astrup, B.K. Siesjo, and L. Symon Thresholds in cerebral ischemia - the ischemic penumbra Stroke 12 1981 723 725
2. A.K. Bruchey, and F. Gonzalez-Lima Behavioral, physiological and biochemical hormetic responses to the autoxidizable dye methylene blue Am. J. Pharmacol. Toxicol. 3 2008 72 79
3. N.L. Callaway, P.D. Riha, A.K. Bruchey, Z. Munshi, and F. Gonzalez-Lima Methylene blue improves brain oxidative metabolism and memory retention in rats Pharmacol. Biochem. Behav. 77 2004 175 181
4. E.E. Congdon, J.W. Wu, N. Myeku, Y.H. Figueroa, M. Herman, P.S. Marinec, J.E. Gestwicki, C.A. Dickey, W.H. Yu, and K.E. Duff Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo Autophagy 8 2012 609 622
5. T.Q. Duong, J.J. Ackerman, H.S. Ying, and J.J. Neil Evaluation of extra- and intracellular apparent diffusion in normal and globally ischemic rat brain via 19F NMR Magn. Reson. Med. 40 1998 1 13
6. S. Huang, F. Du, Y.Y. Shih, Q. Shen, F. Gonzalez-Lima, and T.Q. Duong Methylene blue potentiates stimulus-evoked fMRI responses and cerebral oxygen consumption during normoxia and hypoxia NeuroImage 72 2013 237 242
7. A.L. Lin, E. Poteet, F. Du, R.C. Gourav, R. Liu, Y. Wen, A. Bresnen, S. Huang, P.T. Fox, S.H. Yang, and T.Q. Duong Methylene blue as a cerebral metabolic and hemodynamic enhancer PLoS One 7 2012 e46585
8. X. Meng, M. Fisher, Q. Shen, C.H. Sotak, and T.Q. Duong Characterizing the diffusion/perfusion mismatch in experimental focal cerebral ischemia Ann. Neurol. 55 2004 207 212
9. M.E. Moseley, Y. Cohen, J. Mintorovitch, L. Chileuitt, H. Shimizu, J. Kucharczyk, M.F. Wendland, and P.R. Weinstein Early detection of regional cerebral ischemia in cats: comparison of diffusion- and T2-weighted MRI and spectroscopy Magn. Reson. Med. 14 1990 330 346
10. G.J. Naylor, B. Martin, S.E. Hopwood, and Y. Watson A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis Biol. Psychiatry 21 1986 915 920
11. J.C. O'Leary 3rd, Q. Li, P. Marinec, L.J. Blair, E.E. Congdon, A.G. Johnson, U.K. Jinwal, J. Koren 3rd, J.R. Jones, C. Kraft, M. Peters, J.F. Abisambra, K.E. Duff, E.J. Weeber, J.E. Gestwicki, and C.A. Dickey Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden Mol. Neurodegener. 5 2010 45 55
12. C. Peter, D. Hongwan, A. Kupfer, and B.H. Lauterburg Pharmacokinetics and organ distribution of intravenous and oral methylene blue Eur. J. Clin. Pharmacol. 56 2000 247 250
13. J.C. Rojas, A.K. Bruchey, and F. Gonzalez-Lima Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue Prog. Neurobiol. 96 2012 32 45
14. J.C. Rojas, J.M. John, J. Lee, and F. Gonzalez-Lima Methylene blue provides behavioral and metabolic neuroprotection against optic neuropathy Neurotoxic. Res. 15 2009 260 273
15. G. Schlaug, A. Benfield, A.E. Baird, B. Siewert, K.O. Lovblad, R.A. Parker, R.R. Edelman, and S. Warach The ischemic penumbra: operationally defined by diffusion and perfusion MRI Neurology 53 1999 1528 1537
16. Q. Shen, F. Du, S. Huang, P. Rodriguez, L.T. Watts, and T.Q. Duong Neuroprotective efficacy of methylene blue in ischemic stroke: an MRI study PLoS One 8 2013 e79833
17. Q. Shen, H. Ren, H. Cheng, M. Fisher, and T.Q. Duong Functional, perfusion and diffusion MRI of acute focal ischemic brain injury J. Cereb. Blood Flow Metab. 25 2005 1265 1279
18. I. Walter-Sack, J. Rengelshausen, H. Oberwittler, J. Burhenne, O. Mueller, P. Meissner, and G. Mikus High absolute bioavailability of methylene blue given as an aqueous oral formulation Eur. J. Clin. Pharmacol. 65 2009 179 189
19. L.T. Watts, J. Long, J. Chemello, S. Van Koughnet, A. Fernandez, S. Huang, Q. Shen, and T.Q. Duong Methylene blue is neuroprotective against mild traumatic brain injury J. Neurotrauma. 31 2014 1063 1071
20. 2 consumption in focal cerebral ischaemia Neurol. Res. 16 1994 449 455
21. Y. Wen, W. Li, E.C. Poteet, L. Xie, C. Tan, L.J. Yan, X. Ju, R. Liu, H. Qian, M.A. Marvin, M.S. Goldberg, H. She, Z. Mao, J.W. Simpkins, and S.H. Yang Alternative mitochondrial electron transfer as a novel strategy for neuroprotection J. Biol. Chem. 286 2011 16504 16515
22. C. Wischik, and R. Staff Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of tau-aggregation inhibitor therapy J. Nutr. Health Aging 13 2009 367 369
23. C.M. Wischik, P. Bentham, D.J. Wischik, and K.M. Seng O3-04-07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate alzheimer's disease over 50 weeks Alzheimer's Dement. 4 2008 T167
24. World Health Organization The Top Ten Causes of Death. 310 2011 2
25. X. Zhang, J.C. Rojas, and F. Gonzalez-Lima Methylene blue prevents neurodegeneration caused by rotenone in the retina Neurotoxic. Res. 9 2006 47 57